Previous 10 | Next 10 |
Medical robotics firm Myomo (NYSE:MYO) said its Chinese joint venture firm Jiangxi Myomo Medical Assistive Appliance had paid a portion of the technology license fee. The company said it received $1M of the total $2.7M license fee during March, which will be accounted for as revenue duri...
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, provides an update on the status of its joint ve...
Gainers: AgriFORCE Growing Systems (NASDAQ:AGRI) +159%. Arcadia Biosciences (NASDAQ:RKDA) +44%. CEA Industries (NASDAQ:CEAD) +32%. Enservco (NYSE:ENSV) +30%. Ebix (NASDAQ:EBIX) +27%. Pop Culture Group (NASDAQ:CPOP) +26%. Natera (NASDAQ:NTRA) +24%. Kala Pharmaceuticals (NASDAQ:KALA) +21%. iPow...
Gainers: Kala Pharmaceuticals (NASDAQ:KALA) +20%. Natera (NASDAQ:NTRA) +17%. Chemomab Therapeutics (NASDAQ:CMMB) +13%. Selecta Biosciences (NASDAQ:SELB) +11%. Longeveron (NASDAQ:LGVN) +7%. Losers: Sunshine Biopharma (NASDAQ:SBFM) -32%. My...
Myomo, Inc. (MYO) Q4 2021 Earnings Conference Call March 9, 2022, 4:30 PM ET Company Participants Paul Gudonis – Chief Executive Officer Dave Henry – Chief Financial Officer Kim Golodetz – LHA Investor Relations Conference Call Participants Scott Henry – Roth Capit...
Myomo press release (NYSE:MYO): Q4 GAAP EPS of -$0.52 misses by $0.03. Revenue of $4.0M (+5.5% Y/Y) beats by $1.01M. For further details see: Myomo GAAP EPS of -$0.52 misses by $0.03, revenue of $4.0M beats by $1.01M
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, announces that management will participate in tw...
Fourth quarter revenue of $4.0 million up 6% over prior year, full year revenue of $13.9 million up 83% over 2020 Fourth quarter gross margin of 77.4% up 400 basis points over prior year Conference call begins at 4:30 p.m. Eastern time today Myomo, Inc. (NY...
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial re...
Brings the total number of patents issued on the MyoPro® device globally to 20 Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering fr...
News, Short Squeeze, Breakout and More Instantly...
2024-07-10 17:00:05 ET Scott Henry from Industrial Alliance Securities issued a price target of $5.75 for MYO on 2024-07-10 15:33:00. The adjusted price target was set to $5.75. At the time of the announcement, MYO was trading at $4.97. The overall price target consensus...
2024-07-10 16:15:02 ET Alliance Global Partners analyst issues BUY recommendation for MYO on July 10, 2024 03:33PM ET. The previous analyst recommendation was Buy. MYO was trading at $4.97 at issue of the analyst recommendation. The overall analyst consensus : BUY. C...
2024-07-09 10:30:11 ET Lake Street analyst issues BUY recommendation for MYO on July 9, 2024 08:45AM ET. The previous analyst recommendation was Buy. MYO was trading at $4.07 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst...